Plus Therapeutics (PSTV)
(Delayed Data from NSDQ)
$1.66 USD
-0.03 (-1.77%)
Updated Apr 29, 2024 12:35 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PSTV 1.66 -0.03(-1.77%)
Will PSTV be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PSTV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PSTV
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
PSTV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Plus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
Other News for PSTV
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
Plus Therapeutics receives $3M award recommendation from U.S. DOD
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
Plus Therapeutics appoints Andrew Brenner, Barbara Blouw to management team